The dietary supplement 5-hydroxytryptophan and urinary 5-hydroxyindole acetic acid
During an appointment to sign consent for endoscopy of the upper and lower gastrointestinal tract, the patient reported that, for the last 18 months, she had been taking 5- hydroxytryptophan (5-HTP, 100 mg daily, Natural Factors, Coquitlam, BC), which she had purchased from a local health food store...
Gespeichert in:
| Veröffentlicht in: | Canadian Medical Association journal (CMAJ) 2008-04, Vol.178 (8), p.993-993 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 993 |
|---|---|
| container_issue | 8 |
| container_start_page | 993 |
| container_title | Canadian Medical Association journal (CMAJ) |
| container_volume | 178 |
| creator | Preshaw, Roy M Leavitt, Daniel Hoag, Gordon |
| description | During an appointment to sign consent for endoscopy of the upper and lower gastrointestinal tract, the patient reported that, for the last 18 months, she had been taking 5- hydroxytryptophan (5-HTP, 100 mg daily, Natural Factors, Coquitlam, BC), which she had purchased from a local health food store. The patient was advised to stop taking this supplement, and a 24-hour urine collection to test for 5-hydroxyindole acetic acid was repeated 2 weeks later. At this time, the 24-hour excretion of 5-hydroxyindole acetic acid was 18 ìmol. Her diarrhea also improved and had not returned 6 months later. We found no dose-response studies of 5-hydroxyindole acetic acid excretion levels in humans following oral ingestion of 5-hydroxytryptophan. However, our patient, who was taking a regular dose of 100 mg of 5-hydroxytryptophan daily, excreted a 5-hydroxyindole acetic acid level 10 times the normal upper limit in 24 hours. We did not assess the actual amount of 5-hydroxytryptophan in the commercial preparation. |
| doi_str_mv | 10.1503/cmaj.071569 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2276553</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A177439742</galeid><sourcerecordid>A177439742</sourcerecordid><originalsourceid>FETCH-LOGICAL-c609t-1914310cb6cf5cc9515184896c4aaafb21373f5e680bc42cbfecc0623c14d5c23</originalsourceid><addsrcrecordid>eNqVkktr3DAURk1paaZpV90X00WhFE_1tK1NIYQ-AqGFNF0L-Voea7AlR5JL5t9XwwzJGLKptBDoHh0uV1-WvcVojTmin2FU2zWqMC_Fs2yFWV0XhBLxPFuhmqCCClaeZa9C2KK0KKleZme4pgIJKlbZzW2v89boqPwuD_M0DXrUNua86Hetd_e76HdTdFOvbK5sm8_e2D36UDe2dYPOFehoIB2mfZ296NQQ9JvjeZ79-fb19vJHcf3r-9XlxXUBJRKxwAIzihE0JXQcQHDMcc1qUQJTSnUNwbSiHddljRpgBJpOA6CSUMCs5UDoefbl4J3mZtQtpLa9GuTkzZg6lE4ZuaxY08uN-ysJqUrOaRK8Pwq8u5t1iHLrZm9Tz5IglkZEWJmg4gBt1KClsZ1LLthoq5PSWd2ZdH2Bq4pRUTHyKF3wMJk7eQqtn4DSbvVo4Enrx8WDxER9HzdqDkFe_b75D_bnkv1wwvZaDbEPbpijcTYswU8HELwLwevuYc4YyX0M5T6G8hDDRL87_ZpH9pg7-g9cOtYa</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>204839246</pqid></control><display><type>article</type><title>The dietary supplement 5-hydroxytryptophan and urinary 5-hydroxyindole acetic acid</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Preshaw, Roy M ; Leavitt, Daniel ; Hoag, Gordon</creator><creatorcontrib>Preshaw, Roy M ; Leavitt, Daniel ; Hoag, Gordon</creatorcontrib><description>During an appointment to sign consent for endoscopy of the upper and lower gastrointestinal tract, the patient reported that, for the last 18 months, she had been taking 5- hydroxytryptophan (5-HTP, 100 mg daily, Natural Factors, Coquitlam, BC), which she had purchased from a local health food store. The patient was advised to stop taking this supplement, and a 24-hour urine collection to test for 5-hydroxyindole acetic acid was repeated 2 weeks later. At this time, the 24-hour excretion of 5-hydroxyindole acetic acid was 18 ìmol. Her diarrhea also improved and had not returned 6 months later. We found no dose-response studies of 5-hydroxyindole acetic acid excretion levels in humans following oral ingestion of 5-hydroxytryptophan. However, our patient, who was taking a regular dose of 100 mg of 5-hydroxytryptophan daily, excreted a 5-hydroxyindole acetic acid level 10 times the normal upper limit in 24 hours. We did not assess the actual amount of 5-hydroxytryptophan in the commercial preparation.</description><identifier>ISSN: 0820-3946</identifier><identifier>EISSN: 1488-2329</identifier><identifier>DOI: 10.1503/cmaj.071569</identifier><identifier>PMID: 18390939</identifier><identifier>CODEN: CMAJAX</identifier><language>eng</language><publisher>Canada: CMA Impact Inc</publisher><subject>5-Hydroxytryptophan - administration & dosage ; 5-Hydroxytryptophan - adverse effects ; Acetic acid ; Antidepressive Agents, Second-Generation - administration & dosage ; Antidepressive Agents, Second-Generation - adverse effects ; Carcinoid ; Causes of ; Complications and side effects ; Diagnosis ; Diarrhea ; Diarrhea - chemically induced ; Dietary supplements ; Drug therapy ; Female ; Humans ; Hydroxyindoleacetic Acid - urine ; Measurement ; Middle Aged ; Phytotherapy - adverse effects ; Practice ; Urine</subject><ispartof>Canadian Medical Association journal (CMAJ), 2008-04, Vol.178 (8), p.993-993</ispartof><rights>COPYRIGHT 2008 CMA Impact Inc.</rights><rights>Copyright Canadian Medical Association Apr 8, 2008</rights><rights>2008 Canadian Medical Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c609t-1914310cb6cf5cc9515184896c4aaafb21373f5e680bc42cbfecc0623c14d5c23</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2276553/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2276553/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,861,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18390939$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Preshaw, Roy M</creatorcontrib><creatorcontrib>Leavitt, Daniel</creatorcontrib><creatorcontrib>Hoag, Gordon</creatorcontrib><title>The dietary supplement 5-hydroxytryptophan and urinary 5-hydroxyindole acetic acid</title><title>Canadian Medical Association journal (CMAJ)</title><addtitle>CMAJ</addtitle><description>During an appointment to sign consent for endoscopy of the upper and lower gastrointestinal tract, the patient reported that, for the last 18 months, she had been taking 5- hydroxytryptophan (5-HTP, 100 mg daily, Natural Factors, Coquitlam, BC), which she had purchased from a local health food store. The patient was advised to stop taking this supplement, and a 24-hour urine collection to test for 5-hydroxyindole acetic acid was repeated 2 weeks later. At this time, the 24-hour excretion of 5-hydroxyindole acetic acid was 18 ìmol. Her diarrhea also improved and had not returned 6 months later. We found no dose-response studies of 5-hydroxyindole acetic acid excretion levels in humans following oral ingestion of 5-hydroxytryptophan. However, our patient, who was taking a regular dose of 100 mg of 5-hydroxytryptophan daily, excreted a 5-hydroxyindole acetic acid level 10 times the normal upper limit in 24 hours. We did not assess the actual amount of 5-hydroxytryptophan in the commercial preparation.</description><subject>5-Hydroxytryptophan - administration & dosage</subject><subject>5-Hydroxytryptophan - adverse effects</subject><subject>Acetic acid</subject><subject>Antidepressive Agents, Second-Generation - administration & dosage</subject><subject>Antidepressive Agents, Second-Generation - adverse effects</subject><subject>Carcinoid</subject><subject>Causes of</subject><subject>Complications and side effects</subject><subject>Diagnosis</subject><subject>Diarrhea</subject><subject>Diarrhea - chemically induced</subject><subject>Dietary supplements</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Hydroxyindoleacetic Acid - urine</subject><subject>Measurement</subject><subject>Middle Aged</subject><subject>Phytotherapy - adverse effects</subject><subject>Practice</subject><subject>Urine</subject><issn>0820-3946</issn><issn>1488-2329</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqVkktr3DAURk1paaZpV90X00WhFE_1tK1NIYQ-AqGFNF0L-Voea7AlR5JL5t9XwwzJGLKptBDoHh0uV1-WvcVojTmin2FU2zWqMC_Fs2yFWV0XhBLxPFuhmqCCClaeZa9C2KK0KKleZme4pgIJKlbZzW2v89boqPwuD_M0DXrUNua86Hetd_e76HdTdFOvbK5sm8_e2D36UDe2dYPOFehoIB2mfZ296NQQ9JvjeZ79-fb19vJHcf3r-9XlxXUBJRKxwAIzihE0JXQcQHDMcc1qUQJTSnUNwbSiHddljRpgBJpOA6CSUMCs5UDoefbl4J3mZtQtpLa9GuTkzZg6lE4ZuaxY08uN-ysJqUrOaRK8Pwq8u5t1iHLrZm9Tz5IglkZEWJmg4gBt1KClsZ1LLthoq5PSWd2ZdH2Bq4pRUTHyKF3wMJk7eQqtn4DSbvVo4Enrx8WDxER9HzdqDkFe_b75D_bnkv1wwvZaDbEPbpijcTYswU8HELwLwevuYc4YyX0M5T6G8hDDRL87_ZpH9pg7-g9cOtYa</recordid><startdate>20080408</startdate><enddate>20080408</enddate><creator>Preshaw, Roy M</creator><creator>Leavitt, Daniel</creator><creator>Hoag, Gordon</creator><general>CMA Impact Inc</general><general>CMA Impact, Inc</general><general>Canadian Medical Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISN</scope><scope>ISR</scope><scope>3V.</scope><scope>4T-</scope><scope>4U-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>8FV</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M3G</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20080408</creationdate><title>The dietary supplement 5-hydroxytryptophan and urinary 5-hydroxyindole acetic acid</title><author>Preshaw, Roy M ; Leavitt, Daniel ; Hoag, Gordon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c609t-1914310cb6cf5cc9515184896c4aaafb21373f5e680bc42cbfecc0623c14d5c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>5-Hydroxytryptophan - administration & dosage</topic><topic>5-Hydroxytryptophan - adverse effects</topic><topic>Acetic acid</topic><topic>Antidepressive Agents, Second-Generation - administration & dosage</topic><topic>Antidepressive Agents, Second-Generation - adverse effects</topic><topic>Carcinoid</topic><topic>Causes of</topic><topic>Complications and side effects</topic><topic>Diagnosis</topic><topic>Diarrhea</topic><topic>Diarrhea - chemically induced</topic><topic>Dietary supplements</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Hydroxyindoleacetic Acid - urine</topic><topic>Measurement</topic><topic>Middle Aged</topic><topic>Phytotherapy - adverse effects</topic><topic>Practice</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Preshaw, Roy M</creatorcontrib><creatorcontrib>Leavitt, Daniel</creatorcontrib><creatorcontrib>Hoag, Gordon</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Canada</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>University Readers</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Canadian Business & Current Affairs Database</collection><collection>Canadian Business & Current Affairs Database (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>ProQuest Research Library</collection><collection>ProQuest Science Journals</collection><collection>CBCA Reference & Current Events</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Canadian Medical Association journal (CMAJ)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Preshaw, Roy M</au><au>Leavitt, Daniel</au><au>Hoag, Gordon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The dietary supplement 5-hydroxytryptophan and urinary 5-hydroxyindole acetic acid</atitle><jtitle>Canadian Medical Association journal (CMAJ)</jtitle><addtitle>CMAJ</addtitle><date>2008-04-08</date><risdate>2008</risdate><volume>178</volume><issue>8</issue><spage>993</spage><epage>993</epage><pages>993-993</pages><issn>0820-3946</issn><eissn>1488-2329</eissn><coden>CMAJAX</coden><abstract>During an appointment to sign consent for endoscopy of the upper and lower gastrointestinal tract, the patient reported that, for the last 18 months, she had been taking 5- hydroxytryptophan (5-HTP, 100 mg daily, Natural Factors, Coquitlam, BC), which she had purchased from a local health food store. The patient was advised to stop taking this supplement, and a 24-hour urine collection to test for 5-hydroxyindole acetic acid was repeated 2 weeks later. At this time, the 24-hour excretion of 5-hydroxyindole acetic acid was 18 ìmol. Her diarrhea also improved and had not returned 6 months later. We found no dose-response studies of 5-hydroxyindole acetic acid excretion levels in humans following oral ingestion of 5-hydroxytryptophan. However, our patient, who was taking a regular dose of 100 mg of 5-hydroxytryptophan daily, excreted a 5-hydroxyindole acetic acid level 10 times the normal upper limit in 24 hours. We did not assess the actual amount of 5-hydroxytryptophan in the commercial preparation.</abstract><cop>Canada</cop><pub>CMA Impact Inc</pub><pmid>18390939</pmid><doi>10.1503/cmaj.071569</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0820-3946 |
| ispartof | Canadian Medical Association journal (CMAJ), 2008-04, Vol.178 (8), p.993-993 |
| issn | 0820-3946 1488-2329 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2276553 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | 5-Hydroxytryptophan - administration & dosage 5-Hydroxytryptophan - adverse effects Acetic acid Antidepressive Agents, Second-Generation - administration & dosage Antidepressive Agents, Second-Generation - adverse effects Carcinoid Causes of Complications and side effects Diagnosis Diarrhea Diarrhea - chemically induced Dietary supplements Drug therapy Female Humans Hydroxyindoleacetic Acid - urine Measurement Middle Aged Phytotherapy - adverse effects Practice Urine |
| title | The dietary supplement 5-hydroxytryptophan and urinary 5-hydroxyindole acetic acid |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T17%3A34%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20dietary%20supplement%205-hydroxytryptophan%20and%20urinary%205-hydroxyindole%20acetic%20acid&rft.jtitle=Canadian%20Medical%20Association%20journal%20(CMAJ)&rft.au=Preshaw,%20Roy%20M&rft.date=2008-04-08&rft.volume=178&rft.issue=8&rft.spage=993&rft.epage=993&rft.pages=993-993&rft.issn=0820-3946&rft.eissn=1488-2329&rft.coden=CMAJAX&rft_id=info:doi/10.1503/cmaj.071569&rft_dat=%3Cgale_pubme%3EA177439742%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=204839246&rft_id=info:pmid/18390939&rft_galeid=A177439742&rfr_iscdi=true |